Trade Vir Biotechnology ^VIR

Vir Biotechnology, Inc. (VIR) - What Are Investment Firms Thinking About This Stock?

Hepatitis B Virus (HBV) Infection Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Ascletis Pharma, Shanghai HEP Pharma, Romark Lab, GSK | ABNewswire

Vir Biotechnology (NASDAQ:VIR) & REGENXBIO (NASDAQ:RGNX) Head-To-Head Survey - Stock Observer

Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative? - Simply Wall St News

Could Vir Biotechnology (VIR) Be Above Fair Value After Recent Pipeline News?

I'm Taking Out Some 'Insurance' on My Portfolio With These 2 Stocks

What Could Gilead Sciences (GILD) New Solid Tumor Partnership Mean For Oncology?

Gilead Sciences, Inc. $GILD Stake Trimmed by Curated Wealth Partners LLC - Zolmax

Vir Biotechnology and Gilead Sciences Forge $1.88 Billion Collaboration for Solid Tumor Cancer Therapies, ETPharma

Vir partners with Gilead in $1.8B+ deal for T-cell engagers

Verastem focuses on KRAS G12D therapy, reports 41% ORR in PDAC

Vir Biotechnology Partners With Gilead On Next-Generation Cancer Immunotherapy Programs

Vir Biotechnology Shares Jump on Gilead Cancer Collaboration | Morningstar

Vir CEO sees 'opportunity to do more deals' after striking $1.9B Gilead pact for dual-masked TCEs

Vir Biotechnology (NASDAQ:VIR) Shares Gap Up - What's Next? - Daily Political

Is FDA Fast Track Status Altering The Investment Case For Vir Biotechnology (VIR)?

Is Vir Biotechnology (VIR) Cheap On Fast Track News And SOLSTICE Data Hopes?

Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High - Here's What Happened

Vir Biotechnology (NASDAQ:VIR) Shares Down 6.5% - Time to Sell? - Stock Observer

Vir Biotechnology (NASDAQ:VIR) Shares Climb 6.1% - Here's Why - Stock Observer

Vir Biotechnology (NASDAQ:VIR) Shares Down 6.5% - Here's What Happened

Vir Biotechnology (NASDAQ:VIR) Stock Bumped Down to "Strong Sell" by Zacks Research - Markets Daily

Vir Biotechnology (NASDAQ:VIR) Cut to "Strong Sell" at Zacks Research

How Upcoming SOLSTICE Phase 2 HDV Data Could Shape Vir Biotechnology's (VIR) Investment Narrative

VIR Maintains by HC Wainwright & Co. -- Price Target Raised to $

Vir Biotechnology (NASDAQ:VIR) Given New $22.00 Price Target at HC Wainwright

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026 | Morningstar

Vir Biotechnology (VIR) Could Be 48% Undervalued Following Its CFO Appointment

Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Rated "Moderate Buy" by Sell-Side Brokerages

CoreWeave Stock Forecast 2026–2030: Can CRWV Recover From the AI Debt Sell-Off?

Pound to Rand Forecast: Can GBP/ZAR Break Above 22?

Nebius Stock Price Prediction 2026–2030: Can AI Cloud Growth Justify the Cost?

Eli Lilly Stock Forecast 2026–2030: Can LLY Break Above $1,300 After Its 7% Five-Session Rally?

Is Tesla Stock a Good Buy Right Now? Earnings, AI Growth and Valuation Risks

Is Oracle a Good Buy Right Now? Growth, Valuation and Long-Term Risks

Best Stock CFD Broker in 2026: 9 Platforms Compared

Is SpaceX a Good Stock to Buy in 2026?

Best Gold Stock to Buy Now: 6 Gold Stocks to Watch in 2026

Advanced CFD Trading Tools Review: Which Tools Can Improve Your Trading Decisions?

Tesla Stock Jumps 5.21% as Barclays Upgrade Fuels SpaceX Merger Optimism

Anthropic IPO Prospectus Highlights: Astronomical Growth Meets Unmistakable Risks

SK Hynix Q3 2026 Earnings Date: Can HBM4 Demand Deliver Another Record Profit?

Gold Price Today: Bullion Holds Below $4,000 Ahead of Fed Decision

Microsoft Earnings Preview: Can Azure Growth Justify Rising AI Spending?

US Dollar Index Edges Lower Ahead of Fed Decision and Big Tech Earnings

Fed Rate Decision Preview: Will Kevin Warsh Hold Rates at 4% and Signal a December Hike?

Bitcoin Price Today Falls Below $80,000 as ETF Outflows and Liquidations Deepen the Sell-Off